Is Female Sexual Dysfunction the Next Big Disease?
Interview with Sex, Lies, and Pharmaceuticals author Ray Moynihan
Sex, Lies, and Pharmaceuticals: How Drug Companies Plan to Profit from Female Sexual Dysfunction, Ray Moynihan and Dr. Barbara Mintzes (Greystone Books; October 15, 2010; 978-1-55365-508-4; 17.95; Original Paperback)
Interviewer: You write in your new book Sex, Lies, and Pharmaceuticals that alongside Viagra, Sex and the City and the media sexualization of girl children is a paradoxical sexual insecurity and that Big Pharma exploits this anxiety, transforming common sexual difficulties into medical conditions.
Moynihan: Yes, the books reveals how the pharmaceutical industry is no longer simply sponsoring medical science. With the new conditions called "Hypoactive Sexual Desire Disorder," and "Female Sexual Dysfunction" the drug companies are in some cases actually helping to construct the basic scientific building blocks. The aim is to build the market for the so called 'pink' Viagra. The book looks at how industry is exploring different routes - a testosterone patch, an antidepressant and a drug affecting blood flow.
Interviewer: FDA advisory committees voted against Procter & Gamble's testosterone patch in 2004 and Boehringer Ingelheim's antidepressant flibanserin in June.
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).
2
2
